Study of Atorvastatin Dose Dependent Reduction of Proteinuria

The Renal Protective Effects of Low-dose and High-dose Atorvastatin in Patients With Glomerular Disease and Proteinuria: a Randomized Controlled Double Blinded Study

Randomized controlled double blind study of parallel groups to evaluate the comparative effects of low-dose of atorvastatin on proteinuria in patients with stage 3 or 4 chronic kidney disease.

Inclusion Criteria:

• Age of 18 and over
• Stage 3 or 4 chronic kidney disease (modified MDRD)
• proteinuria of > 1g/d on ACEi and/or ARB, or proteinuria of > 1g/d with intolerance or contraindication to ACEi and/or ARB
• blood pressure < 130/80 mmHg or < 140/90 mmHg in patients with five or more antihypertensive drugs
• stable renal function

Exclusion Criteria:

• rapid progression of renal failure
• immunosuppressive therapy within the past 3 months
• need a renal replacement therapy within 8 months
• definite history of chronic liver disease, or abnormal liver function
• evidence of active inflammatory muscle disease
• definite previous adverse reaction to a statin
• concurrent treatment with a contraindicated drug (fibrate, macrolide antibiotic, systemic use of imidazole or triazole antifungals, protease-inhibitors, ciclosporin)
• child bearing potential
• known to be poorly compliant with clinic visits or prescribed medication